TY - JOUR
T1 - Glioblastoma Therapy
T2 - Rationale for a Mesenchymal Stem Cell-based Vehicle to Carry Recombinant Viruses
AU - Ali, Sakhawat
AU - Xia, Qin
AU - Muhammad, Tahir
AU - Liu, Liqun
AU - Meng, Xinyi
AU - Bars-Cortina, David
AU - Khan, Aamir Ali
AU - Huang, Yinghui
AU - Dong, Lei
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/2
Y1 - 2022/2
N2 - Evasion of growth suppression is among the prominent hallmarks of cancer. Phosphatase and tensin homolog (PTEN) and p53 tumor-suppressive pathways are compromised in most human cancers, including glioblastoma (GB). Hence, these signaling pathways are an ideal point of focus for novel cancer therapeutics. Recombinant viruses can selectivity kill cancer cells and carry therapeutic genes to tumors. Specifically, oncolytic viruses (OV) have been successfully employed for gene delivery in GB animal models and showed potential to neutralize immunosuppression at the tumor site. However, the associated systemic immunogenicity, inefficient transduction of GB cells, and inadequate distribution to metastatic tumors have been the major bottlenecks in clinical studies. Mesenchymal stem cells (MSCs), with tumor-tropic properties and immune privilege, can improve OVs targeting. Remarkably, combining the two approaches can address their individual issues. Herein, we summarize findings to advocate the reactivation of tumor suppressors p53 and PTEN in GB treatment and use MSCs as a “Trojan horse” to carry oncolytic viral cargo to disseminated tumor beds. The integration of MSCs and OVs can emerge as the new paradigm in cancer treatment. Graphical abstract: [Figure not available: see fulltext.]
AB - Evasion of growth suppression is among the prominent hallmarks of cancer. Phosphatase and tensin homolog (PTEN) and p53 tumor-suppressive pathways are compromised in most human cancers, including glioblastoma (GB). Hence, these signaling pathways are an ideal point of focus for novel cancer therapeutics. Recombinant viruses can selectivity kill cancer cells and carry therapeutic genes to tumors. Specifically, oncolytic viruses (OV) have been successfully employed for gene delivery in GB animal models and showed potential to neutralize immunosuppression at the tumor site. However, the associated systemic immunogenicity, inefficient transduction of GB cells, and inadequate distribution to metastatic tumors have been the major bottlenecks in clinical studies. Mesenchymal stem cells (MSCs), with tumor-tropic properties and immune privilege, can improve OVs targeting. Remarkably, combining the two approaches can address their individual issues. Herein, we summarize findings to advocate the reactivation of tumor suppressors p53 and PTEN in GB treatment and use MSCs as a “Trojan horse” to carry oncolytic viral cargo to disseminated tumor beds. The integration of MSCs and OVs can emerge as the new paradigm in cancer treatment. Graphical abstract: [Figure not available: see fulltext.]
KW - Mesenchymal stem cells
KW - Oncolytic viruses
KW - Targeted delivery
KW - Tumor suppressors
UR - http://www.scopus.com/inward/record.url?scp=85111531530&partnerID=8YFLogxK
U2 - 10.1007/s12015-021-10207-w
DO - 10.1007/s12015-021-10207-w
M3 - Review article
C2 - 34319509
AN - SCOPUS:85111531530
SN - 2629-3269
VL - 18
SP - 523
EP - 543
JO - Stem Cell Reviews and Reports
JF - Stem Cell Reviews and Reports
IS - 2
ER -